Ticker: NBIX

Neurocrine Biosciences

Biotech Healthcare Drug Manufacturers - Specialty & Generic
Price 175.77
Reco Buy Potential 74 Risk 31 Updated 2026-07-27

Forecast impact

positive
Target +13.8% target fill 87.9%
Reaction D5 pending · D10 pending fresh confirmed · market trust
Impact Potential +6 · Risk -3 valid until 2026-08-20

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases. Its core products include therapies for conditions such as tardive dyskinesia and endometriosis. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations with other pharmaceutical firms. Neurocrine's commitment to innovation is reflected in its robust pipeline of drug candidates aimed at addressing unmet medical needs.

Investment Profile

The investment profile of Neurocrine Biosciences is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The absence of dividends suggests a reinvestment strategy aimed at long-term value creation. Investors may find the stock suitable for a medium to long-term horizon, with moderate liquidity reflecting its market position.

Fundamental metrics (experimental) Updated: 2026-07-23
EPS (TTM) — earnings per share for the last 12 months, $
6.71
Revenue QoQ — quarter-over-quarter revenue growth
1.1%
EPS surprise
15.5%
20d volatility
1.7%
AI recommendation changes
Date Before After Reason
2026-05-16 Hold Buy Strong momentum and positive earnings surprise support growth outlook.
2026-05-08 Hold Strong recent performance and positive momentum indicators.
2026-05-07 Hold Buy Компания демонстрирует положительную динамику цен на акции в краткосрочной перспективе, а также стабильный рост выручки. Умеренный риск обусловлен волатильностью на рынке и отсутствием дивидендов.
Analyst forecasts
Date Analyst Action Target Price Then
2026-07-21 Guggenheim Target Raised 175 → 200 178.1
2026-07-17 Wells Fargo Target Raised 175 → 200 171.55
2026-07-13 Truist Financial Target Raised 155 → 200 175.155
News Page 1 of 1

Nothing yet